Physician profile
David Meredith
NPI 1427041383
$3,996.42
in general payments reported to CMS, 2019-2025
34 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $411 · 2021: $713 · 2022: $473 · 2023: $781 · 2024: $694 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $814.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $413.52 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $372.49 | 2019-2022 | |
| Lilly USA, LLC | $371.98 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $356.40 | 2019-2025 | Farxiga, Breztri, Andexxa |
| Sanofi Pasteur INC. | $209.40 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $196.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.89 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $137.07 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $126.41 | 2022-2025 | Rexulti |
| Pfizer INC. | $117.20 | 2020-2025 | |
| Amgen INC. | $116.99 | 2019-2025 | Evenity, Prolia |
| Biogen, INC. | $78.27 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.05 | 2019-2025 | Trintellix |
| Allergan, INC. | $53.86 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.58 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $39.91 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $37.09 | 2021 | |
| Abbott Laboratories | $28.56 | 2025 | Proclaim |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.20 | 2022 | |
| Merck Sharp & Dohme LLC | $21.81 | 2025 | Vaxneuvance, Proquad, Vaxelis |
| Averitas Pharma INC. | $21.53 | 2023 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.25 | 2025 | Caplyta |
| Organon LLC | $20.00 | 2024 | |
| Capsovision, INC. | $18.75 | 2023 | Capsocam Plus |
| Ethicon US, LLC | $17.54 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.91 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.06 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.00 | 2024 | Nuzyra |
| Esperion Therapeutics, INC. | $14.72 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.